Cerebrolysin is not one peptide but a preparation of many, derived from pig brain. Its research history shows how much harder a mixture is to characterise, and to test, than a single defined compound.
Cerebrolysin · Porcine brain peptide mixture
Nerve cells depend on signals that help them survive stress and adapt after injury. Researchers have asked whether a preparation containing many small brain-derived peptides could stand in for those signals after a stroke or in dementia. Cerebrolysin is the best-known example. The evidence comes mainly from human trials, and the results are contested.
Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of porcine (pig) brain protein. It has no single chemical structure; its identity is defined by the manufacturing process rather than by a sequence. The branded preparation is made by EVER Pharma in Austria and supplied as a solution for injection at 215.2 mg per mL.
The research premise is that the peptide fraction mimics endogenous neurotrophic factors, the body's own signals involved in nerve-cell maintenance and adaptation. Because the material is a mixture, that mechanism cannot be traced to one receptor, and it has been studied mainly in animal models rather than defined at the molecular level (Masliah and Diez-Tejedor, 2012).
Material sold under the Cerebrolysin name as a lyophilised (freeze-dried) powder is a different presentation from the branded solution. Equivalence to the preparation used in the published trials cannot be assumed without characterisation of the specific batch.
The largest body of evidence is in acute ischaemic stroke, where a blood clot blocks supply to part of the brain. The 2023 Cochrane review pooled seven randomised trials with 1,773 participants given Cerebrolysin, or the similar preparation Cortexin, within 48 hours of stroke. It found that the preparations probably make little or no difference to all-cause death (moderate certainty), probably make little or no difference to the total number of people with serious adverse events, but probably increase the number with non-fatal serious adverse events (moderate certainty). None of the included trials reported the review’s prespecified measure of poor functional outcome, death or dependence at follow-up, so the review could not assess disability. The largest single trial, CASTA, randomised 1,070 patients in Asia to ten days of intravenous Cerebrolysin or saline and found no difference on its primary endpoint; a favourable trend in severely affected patients was a post hoc observation the authors said needed confirmation.
In early rehabilitation after stroke, the smaller CARS trial reported better upper-limb motor scores at day 90 with a 21-day intravenous course alongside standard rehabilitation; the authors described the study as exploratory and called for a large confirmatory trial. In vascular dementia, a 2019 Cochrane review of six trials (597 people) found improved cognition scores but rated the evidence very low quality, with high risk of bias, industry funding, and effects that may be too small to be clinically meaningful.
Every trial above used the branded intravenous solution in a defined patient population. Those findings say nothing about a different presentation, route or batch, and a mixture defined by process can differ between sources in ways a purity figure does not capture.
The stroke evidence is limited: probably little or no difference in death (moderate certainty), no pooled result for disability because the trials did not report it, and probably more non-fatal serious adverse events. The dementia and rehabilitation findings rest on small or high-risk-of-bias trials. The neurotrophic mechanism is supported mainly by animal and cell work and has not been shown to explain any clinical result in people.
No Australian registration for Cerebrolysin was identified. The branded preparation is registered as a prescription medicine in a number of countries, including Russia, parts of Eastern Europe and China, and its manufacturer states it is not approved by the US FDA. The lyophilised material supplied here is not that registered product.
Sources and status checked 2026-09-22
Cerebrolysin — sizes and pricing